Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen AsfiledCriticalRoche Innovation Ct Copenhagen As
Priority claimed from PCT/EP2014/063757external-prioritypatent/WO2014207232A1/en
Publication of MA38717A1publicationCriticalpatent/MA38717A1/en
Publication of MA38717B1publicationCriticalpatent/MA38717B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La présente invention concerne des composés oligomères et des conjugués de ceux-ci qui ciblent la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) l'arnm pcsk9 dans une cellule, conduisant à une expression réduite de pcsk9. La réduction de l'expression de pcsk9 est bénéfique pour le traitement de certains troubles médicaux, tels que l'hypercholestérolémie et des troubles associés.The present invention relates to oligomeric compounds and conjugates thereof that target the proprotein convertase subtilisin / kexin type 9 (pcsk9) arnmpcsk9 in a cell, leading to reduced expression of pck9. The reduction of pck9 expression is beneficial for the treatment of certain medical conditions, such as hypercholesterolemia and related disorders.
MA38717A2013-06-272014-06-27
Antisense oligomers and conjugates targeting pcsk9
MA38717B1
(en)